CRVO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

983.33K

-54.52%

-0.644

-19.46%

275.00K

-85.66%

-0.608

+8.48%

350.00K

-80.09%

-0.502

-28.21%

Estimates Revision

The market is revising Downward the revenue expectations for CervoMed Inc. (CRVO) for FY2025, with the revenue forecasts being adjusted by -22.4% over the past three months. During the same period, the stock price has changed by -1.05%.

Revenue Estimates for FY2025

Revise Downward

-22.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+12.49%

In Past 3 Month

Stock Price

Go Down

-1.05%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is 22.75 USD with a low forecast of 19.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.450

Low

19.00

Averages

22.75

High

27.00

Current: 8.450

Low

19.00

Averages

22.75

High

27.00

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$20 -> $19

2025-11-10

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$20 -> $19

2025-11-10

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on CervoMed to $19 from $20 and keeps a Buy rating on the shares. In the wake of Q3 financial results, the firm caught up with CervoMed CFO Bill Elder for further insights, the analyst tells investors in a research note. At the end of Q3 the company has roughly $27.3M in cash, which, per management's view, is expected to fund operations through 3Q26, the analyst notes.

H.C. Wainwright

Raghuram Selvaraju

Neutral -> Buy

upgrade

$25

2025-11-05

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$25

2025-11-05

upgrade

Neutral -> Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju upgraded CervoMed to Buy from Neutral with a $25 price target after the company received written feedback from the FDA aligning on key aspects of its proposed Phase 3 clinical trial of neflamapimod. The parameters on which CervoMed has reached alignment with the FDA "appear eminently logical and reasonable," the analyst tells investors in a research note. H.C. Wainwright believes this a "significant risk-mitigating development" for the company.

Roth Capital

Buy

upgrade

$16 -> $20

2025-10-17

Reason

Roth Capital

Price Target

$16 -> $20

2025-10-17

upgrade

Buy

Reason

Roth Capital raised the firm's price target on CervoMed to $20 from $16 and keeps a Buy rating on the shares. Following a re-analysis of the Phase 2b results, Roth is "convinced" that CervoMed's neflamapimod has the potential to become a new therapy for dementia with Lewy bodies. The firm increased the drug's probability of success to 50% from 40%, prompting the higher price target.

H.C. Wainwright

Neutral

maintain

$11

2025-09-08

Reason

H.C. Wainwright

Price Target

$11

2025-09-08

maintain

Neutral

Reason

H.C. Wainwright set a price target of $11 for CervoMed shares while keeping a Neutral rating on the name. The regulatory outlook for neflamapimod should be clarified in the near-term, the analyst tells investors in a research note. The firm says CervoMed is actively preparing for discussions with the FDA, which management expects to take place during Q4.

D. Boral Capital

Jason Kolbert

Buy

upgrade

$15 -> $31

2025-08-18

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15 -> $31

2025-08-18

upgrade

Buy

Reason

D. Boral Capital analyst Jason Kolbert raised the firm's price target on CervoMed to $31 from $15 and keeps a Buy rating on the shares. The firm increased its probability of clinical success for neflamapimod in dementia with Lewy bodies to 30% from 15% based on recently presented data. The recent results "materially strengthen" the late-stage outlook for the program and address uncertainties, the analyst tells investors in a research note. D. Boral points out that the underdosed patients performed like placebo, while fully dosed patients drove the efficacy signal.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$20 -> $16

2025-08-12

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$20 -> $16

2025-08-12

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on CervoMed to $16 from $20 and keeps a Buy rating on the shares after its Q2 results. Following positive Week 32 Phase 2b OLE data, CervoMed is slated to meet with the FDA in Q4 to discuss the results generated to date and obtain guidance on its Phase 3 study preparations, the analyst tells investors in a research note. Roth has also updated its model that assumes $78M in equity financing, the firm added.

Valuation Metrics

The current forward P/E ratio for CervoMed Inc (CRVO.O) is -3.62, compared to its 5-year average forward P/E of -5.75. For a more detailed relative valuation and DCF analysis to assess CervoMed Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.75

Current PE

-3.62

Overvalued PE

-2.23

Undervalued PE

-9.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.17

Current EV/EBITDA

-1.09

Overvalued EV/EBITDA

-0.12

Undervalued EV/EBITDA

-6.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

17.12

Current PS

39.93

Overvalued PS

27.65

Undervalued PS

6.60

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRVO News & Events

Events Timeline

No data

News

9.0

12-04Globenewswire

CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial

9.0

12-02Globenewswire

CervoMed Reports New Data on Neflamapimod Clinical Trial, Significant GFAP Reduction

9.0

12-02Newsfilter

CervoMed's Neflamapimod Significantly Reduces Neurodegeneration Biomarker GFAP

People Also Watch

Frequently Asked Questions

What is CervoMed Inc (CRVO) stock price today?

The current price of CRVO is 8.45 USD — it has increased 0 % in the last trading day.

What is CervoMed Inc (CRVO)'s business?

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

What is the price predicton of CRVO Stock?

What is CervoMed Inc (CRVO)'s revenue for the last quarter?

CervoMed Inc revenue for the last quarter amounts to 322.57K USD, decreased -83.37 % YoY.

What is CervoMed Inc (CRVO)'s earnings per share (EPS) for the last quarter?

CervoMed Inc. EPS for the last quarter amounts to -0.84 USD, increased 52.73 % YoY.

What changes have occurred in the market's expectations for CervoMed Inc (CRVO)'s fundamentals?

How many employees does CervoMed Inc (CRVO). have?

CervoMed Inc (CRVO) has 15 emplpoyees as of December 15 2025.

What is CervoMed Inc (CRVO) market cap?

Today CRVO has the market capitalization of 78.19M USD.